前列腺癌数字病理人工智能算法:黑箱内部探析
本综述探讨基于数字病理切片的人工智能算法在前列腺癌中的应用进展,包括肿瘤诊断与分级、减少观察者间变异、提供量化肿瘤指标,以及预测预后、治疗反应和分子改变。文章还讨论了临床实施的优势与障碍,强调AI在标准化病理评估和指导临床管理方面的潜力。
要点
- AI算法在前列腺癌诊断和分级中表现可与病理学家相当或更优。
- AI可减少观察者间变异并提供量化肿瘤指标。
- 基于预后金标准(转移或死亡)验证的AI算法展现潜力。
核心结论
- 基于数字病理的AI算法有望标准化前列腺癌病理评估、指导临床管理并改善患者结局。
研究设计与样本
- 本文为叙述性综述,检索并综合近期关于前列腺癌组织病理学AI系统的文献。
主要发现
- AI算法在肿瘤诊断和分级方面与病理学家表现相当,并在减少观察者间变异和提供量化肿瘤指标方面超越病理学家。
- 部分预后算法已针对转移或死亡等金标准患者结局进行基准验证。
- 数字病理AI在预测治疗反应或潜在肿瘤分子改变状态方面呈现新兴作用。
临床怎么用
- AI可辅助病理学家进行前列腺癌诊断和分级,减少观察者间差异。
- 基于预后验证的AI算法可用于风险分层和临床管理指导。
- AI预测治疗反应和分子状态有助于个体化治疗决策。
局限性
- 数字病理和AI算法在临床实践中实施仍存在障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Artificial intelligence (AI) algorithms leveraging digital pathology slides are currently transforming the way urological cancers are diagnosed and graded, and they add additional prognostic, predictive and molecular subtyping information beyond traditional pathological risk stratification. This review explores recent advances in histopathology-based AI systems for prostate cancer. We examine how these algorithms perform relative to pathologists for tumour diagnosis and grading, and the ways in which they surpass pathologists with respect to reducing inter-observer variability and providing quantified tumour metrics. We particularly focus on prognostic algorithms that have been benchmarked against 'gold standard' patient outcomes such as metastasis or death, and we highlight the emerging role of digital pathology-enabled AI for predicting response to therapy or underlying tumour molecular alteration status. Finally, we touch on the advantages of, and barriers to, implementation of digital pathology and histopathology-based AI algorithms in clinical practice. Through this synthesis of current literature, we underscore the emerging potential of AI for standardising pathological assessment, guiding clinical management, and improving patient outcomes in prostate cancer.
引用
- de la Calle CM, Baras AS, Lotan TL, et al. Digital pathology-based artificial intelligence algorithms in prostate cancer: inside the 'black box'. BJU Int. 2026. PMID: 41698677. doi:10.1111/bju.70164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。